Arrowstreet Capital
ACHN

Arrowstreet Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Arrowstreet Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-668,185
Closed -$5.41M – 2785
2016
Q3 		$5.41M Buy
+668,185
New +$5.68M 0.02% 627

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Arrowstreet Capital's ACHN Position: Q4 2016 in Review

Arrowstreet Capital sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 668,185 shares — an estimated $5.41M sold.

Arrowstreet Capital first reported a position in ACHN in Q3 2016 and held it in 1 quarter. The position peaked at $5.41M in Q3 2016. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Arrowstreet Capital reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Arrowstreet Capital sold 668,185 Achillion Pharmaceuticals shares in Q4 2016, an estimated $5.41M.
  • Arrowstreet Capital first reported a position in Achillion Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Arrowstreet Capital's Achillion Pharmaceuticals position peaked at $5.41M in Q3 2016.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Arrowstreet Capital's 13F filing for Q4 2016, filed 15 Feb 2017.